DERM — Journey Medical Corporation

Journey Medical (DERM) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenues: $61.9 million for 2025, up 10% from $56.1 million in 2024.
• Net Product Revenue: $14.7 million from Emrosi since its launch in March 2025.
• Gross Margin: Improved to 66.2% from 62.8% in 2024.
• SG&A Expenses: Increased to $44.4 million, up 10% from $40.2 million in 2024 due to launch-related activities.
• GAAP Net Loss: $11.4 million ($0.47 per share), narrowed from a loss of $14.7 million ($0.72 per share) in 2024.
• Adjusted EBITDA: Positive at $2.9 million, compared to $800,000 in 2024.
• Cash Position: Ended 2025 with $24.1 million, up from $20.3 million in 2024.

2. Strategic Updates and Business Highlights

• Product Launch: Emrosi, an oral treatment for rosacea, launched successfully with strong prescription volume (53,000 prescriptions in 2025).
• Market Access: Approximately 100 million commercial lives have access to Emrosi, with contracts in place with two of the top three group purchasing organizations (GPOs).
• Clinical Validation: Positive Phase III trial results published in JAMA Dermatology; Emrosi's efficacy and safety profile received strong endorsements.
• Sales Force Expansion: Plans to increase the sales force in Q3 2026 to support Emrosi's growth.
• Future Products: Anticipation of launching 1-2 additional dermatology products in 2026.

3. Forward Guidance and Outlook

• 2026 Expectations: Continued growth in Emrosi sales anticipated, with expectations for positive adjusted EBITDA and improved reimbursement rates as health plans adopt Emrosi.
• Prescription Growth: Anticipated annualized prescription run rate for Emrosi expected to exceed 126,000 in 2026.
• Market Position: Positioned for significant growth in the dermatology market, with a focus on expanding prescriber base and improving patient experiences.

4. Bad News, Challenges, or Points of Concern

• Competitive Pressures: Legacy products, particularly the Accutane franchise, faced challenges due to generic competition.
• Prescription Trends: Q1 2026 prescriptions showed a flat trend initially, attributed to insurance deductible resets and adverse weather conditions affecting patient visits.
• Revenue per Script Variability: Concerns about lower revenue per script in Q4, attributed to reimbursement mix and reliance on co-pay assistance programs.
• Timing of Coverage Decisions: The timing of health plan coverage decisions could impact revenue recognition and growth.

5. Notable Q&A Insights

• Prescription Trends: Management acknowledged Q1 challenges but expressed confidence in surpassing Q4 prescription numbers.
• Gross to Net Expectations: Anticipated improvements in gross to net as reimbursement rates improve and coverage expands, with upward pressure expected throughout 2026.
• Inventory Management: Inventory levels were reported as being on track, with no significant concerns raised regarding channel inventory.
• Future Publications: Plans to publish additional clinical data supporting Emrosi's efficacy and economic value, which could enhance market acceptance.

Overall, Journey Medical reported a strong year driven by the successful launch of Emrosi, with a positive outlook for continued growth despite some challenges in the competitive landscape and prescription trends.